← Browse by Condition
Medical Condition
chronic lymphocytic leukemia
Total Trials
11
Recruiting Now
11
Trial Phases
Phase 2, Phase 1, Phase 2, Phase 3
NCT05281809 Phase 2
Recruiting
Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia
Enrollment
30 pts
Location
United States
Sponsor
John Lister
NCT05006716 Phase 1, Phase 2
Recruiting
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Enrollment
614 pts
Location
United States, Austr...
Sponsor
BeOne Medicines
NCT03128879 Phase 2
Recruiting
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
Enrollment
90 pts
Location
United States
Sponsor
M.D. Anderson Cancer Center
NCT03986034 Phase 2
Recruiting
Early Clonal Dynamics During Venetoclax Treatment for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Enrollment
75 pts
Location
United States
Sponsor
National Heart, Lung, and Bloo...
NCT07099443
Recruiting
Determinants of the Response to BTK Degraders (BTKd) in Double Refractory CLL
Enrollment
60 pts
Location
France
Sponsor
Nantes University Hospital
NCT05031897 Phase 2
Recruiting
Two Step Haplo With Radiation Conditioning
Enrollment
63 pts
Location
United States
Sponsor
Thomas Jefferson University
NCT05334069
Recruiting
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Enrollment
2,000 pts
Location
United States
Sponsor
Alliance for Clinical Trials i...
NCT05246345
Recruiting
Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia
Enrollment
50 pts
Location
France
Sponsor
University Hospital, Clermont-...
NCT01804686 Phase 3
Recruiting
A Long-term Extension Study of PCI-32765 (Ibrutinib)
Enrollment
700 pts
Location
United States, Argen...
Sponsor
Janssen Research & Development...
NCT04560322 Phase 2
Recruiting
Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL
Enrollment
40 pts
Location
United States
Sponsor
Massachusetts General Hospital
NCT05702853 Phase 1, Phase 2
Recruiting
Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL
Enrollment
27 pts
Location
United States
Sponsor
Medical University of South Ca...